Prelude Therapeutics Incorporated financials
$3.96+1.28%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $12.1M | $7.0M | $0.00 | $0.00 | — | — |
| Gross profit | $12.1M | $7.0M | $0.00 | $0.00 | — | — |
| Gross margin | 100.0% | 100.0% | — | — | — | — |
| Operating income | -$104.6M | -$139.7M | -$132.3M | -$123.5M | -$113.7M | -$58.8M |
| Net income | -$99.5M | -$127.2M | -$121.8M | -$115.4M | -$111.7M | -$56.9M |
| Net margin | −819.6% | −1816.8% | — | — | — | — |
| Diluted EPS | $-1.29 | $-1.68 | $-2.02 | $-2.44 | $-2.43 | $-4.56 |
| EBITDA | -$102.9M | -$137.9M | -$131.1M | -$122.2M | -$111.5M | -$58.2M |
| Operating cash flow | -$56.3M | -$102.9M | -$107.1M | -$83.7M | -$83.5M | -$46.2M |
| Free cash flow | -$56.4M | -$103.7M | -$110.6M | -$86.7M | -$85.9M | -$46.8M |
| Diluted shares | 77.0M | 75.8M | 60.4M | 47.4M | 46.0M | 12.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $35.3M | $12.5M | $25.3M | $30.6M | $31.8M | $218.3M |
| Short-term investments | $68.0M | $121.1M | $207.6M | $171.1M | $259.4M | — |
| Total debt | $0.00 | $208.0K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $141.3M | $175.5M | $277.7M | $220.5M | $305.1M | $223.6M |
| Total liabilities | $72.7M | $44.1M | $40.6M | $25.1M | $19.2M | $11.4M |
| Shareholders' equity | $68.6M | $131.5M | $237.1M | $195.4M | $285.9M | $212.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology